Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study

PURPOSE: The Recurrence Score test is validated to predict benefit of adjuvant chemotherapy. TransNEOS, a translational study of New Primary Endocrine-therapy Origination Study (NEOS), evaluated whether Recurrence Score results can predict clinical response to neoadjuvant letrozole. METHODS: NEOS is...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwata, Hiroji, Masuda, Norikazu, Yamamoto, Yutaka, Fujisawa, Tomomi, Toyama, Tatsuya, Kashiwaba, Masahiro, Ohtani, Shoichiro, Taira, Naruto, Sakai, Takehiko, Hasegawa, Yoshie, Nakamura, Rikiya, Akabane, Hiromitsu, Shibahara, Yukiko, Sasano, Hironobu, Yamaguchi, Takuhiro, Sakamaki, Kentaro, Bailey, Helen, Cherbavaz, Diana B., Jakubowski, Debbie M., Sugiyama, Naoko, Chao, Calvin, Ohashi, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394785/
https://www.ncbi.nlm.nih.gov/pubmed/30242578
http://dx.doi.org/10.1007/s10549-018-4964-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394785/
https://www.ncbi.nlm.nih.gov/pubmed/30242578
http://dx.doi.org/10.1007/s10549-018-4964-y

Ejemplares similares